Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.41 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | F13A1 | P00488 | 1/20 | 0.38 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.37 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7699509 | 0.82 | NAMPT (0.41) | SLC6A4TACR1SLC6A2SLC6A3OPRD1 | |
| SCHEMBL7095304 | 0.80 | CHRM2 (0.69) | CHRM2CHRM3OPRD1OPRM1MEN1 | |
| SCHEMBL6160138 | 0.77 | SLC6A4 (0.54) | CHRM2CHRM3SLC6A4SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL22797859 | 0.76 | SLC6A2 (0.53) | CHRM2CHRM3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2995935 | 0.74 | SLC6A4 (0.54) | CHRM2CHRM3SLC6A4TACR1SLC6A2 | |
| SCHEMBL7096423 | 0.73 | NPC1 (0.43) | SPHK1MC4RMEN1KMT2A | |
| SCHEMBL23805139 | 0.69 | OPRD1 (0.61) | CHRM2CHRM3SLC6A3OPRD1OPRM1 | |
| Phenethylcarbamic Acid SCHEMBL28146061 | 0.68 | CA12 (0.53) | KDM4EMC4RMEN1KMT2A | |
| SCHEMBL14144500 | 0.68 | SLC6A4 (0.53) | SLC6A4TACR1SLC6A2SLC6A3OPRM1 | |
| SCHEMBL23805121 | 0.68 | OPRM1 (0.45) | CHRM3SLC6A4TACR1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | CHRM2 137/4885CHRM3 161/4885SLC6A4 653/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | CHRM2 128/4885CHRM3 158/4885SLC6A4 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.